Teva Pharma (TEVA) Posts Q3 EPS of $0.89, Beats by 1c
More News related to TEVA
- Protalix BioTherapeutics (PLX) Sees Interest On Renewed Takeover Talk
- Abbott (ABT) sues Teva (TEVA) over its drug for kidney patients, Zemplar
- Merriman Curhan Ford Initiates Coverage on Antares Pharma (AIS) with a Buy; Cutting Edge Drug Delivery Business
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
More News related to Earnings
- Strategist Says $1500/oz Gold Will Lead Oil Above $100/bbl
- Analysts Bullish on Analog Devices (ADI) Following Q4 Results: AmTech, GC Research Upgrade, Citi Lifts Price Target
- UBS Raises Estimates and Price Target on Wal-Mart (WMT)
- Susquehanna Maintains a 'Positive' Rating on Hewlett-Packard (HPQ); Raises PT to $58
- Credit Suisse Maintains an 'Outperform' on Newmont Mining (NEM), Raises PT
Teva Pharmaceutical (NASDAQ: TEVA) reports Q3 EPS of $0.89, 1 cent better than the analyst estimate of $0.88. Revenue for the quarter was $3.55 billion, which compares to the estimate of $3.63 billion.
Related Categories
EarningsStocks Mentioned
-0.16Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
